- Home
- CVKD vs TENX Comparison
CVKD vs TENX Comparison
Compare CVKD & TENX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CVKD
- TENX
- Stock Information
- Founded
- CVKD 2022
- TENX 1967
- Country
- CVKD United States
- TENX United States
- Employees
- CVKD N/A
- TENX N/A
- Industry
- CVKD Medicinal Chemicals and Botanical Products
- TENX Biotechnology: Pharmaceutical Preparations
- Sector
- CVKD Health Care
- TENX Health Care
- Exchange
- CVKD Nasdaq
- TENX Nasdaq
- Market Cap
- CVKD 27.0M
- TENX 27.3M
- IPO Year
- CVKD 2023
- TENX N/A
- Fundamental
- Price
- CVKD $14.13
- TENX $7.50
- Analyst Decision
- CVKD Strong Buy
- TENX Strong Buy
- Analyst Count
- CVKD 1
- TENX 3
- Target Price
- CVKD $32.00
- TENX $16.67
- AVG Volume (30 Days)
- CVKD 25.8K
- TENX 108.2K
- Earning Date
- CVKD 11-07-2025
- TENX 11-12-2025
- Dividend Yield
- CVKD N/A
- TENX N/A
- EPS Growth
- CVKD N/A
- TENX N/A
- EPS
- CVKD N/A
- TENX N/A
- Revenue
- CVKD N/A
- TENX N/A
- Revenue This Year
- CVKD N/A
- TENX N/A
- Revenue Next Year
- CVKD N/A
- TENX N/A
- P/E Ratio
- CVKD N/A
- TENX N/A
- Revenue Growth
- CVKD N/A
- TENX N/A
- 52 Week Low
- CVKD $8.74
- TENX $4.30
- 52 Week High
- CVKD $22.90
- TENX $8.24
- Technical
- Relative Strength Index (RSI)
- CVKD 54.38
- TENX 60.58
- Support Level
- CVKD $12.11
- TENX $6.10
- Resistance Level
- CVKD $14.35
- TENX $7.72
- Average True Range (ATR)
- CVKD 0.66
- TENX 0.50
- MACD
- CVKD -0.08
- TENX -0.04
- Stochastic Oscillator
- CVKD 76.99
- TENX 65.27
About CVKD Cadrenal Therapeutics Inc.
Cadrenal Therapeutics Inc is developing tecarfarin, its drug candidate, for unmet needs in anticoagulation therapy. Tecarfarin is a late-stage novel oral and reversible anticoagulant (blood thinner) designed to prevent heart attacks, strokes, and deaths due to blood clots in patients with rare cardiovascular conditions requiring chronic anticoagulation.
About TENX Tenax Therapeutics Inc.
Tenax Therapeutics Inc is a specialty pharmaceutical company focused on identifying, developing, and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical needs. The company owns North American rights to develop and commercialize levosimendan and has released topline data regarding the Phase 2 clinical trial for the use of levosimendan in the treatment of pulmonary hypertension associated with Heart Failure and preserved Ejection Fraction.